Save on Lunsumio with Coupons, Discounts & Savings Programs

Lunsumio is the brand name for mosunetuzumab-axgb IV infusion.

Lunsumio is available as a 1 mg/mL and 30 mg/30 mL (1 mg/mL) single-dose vial.

Lunsumio is a bispecific CD20-directed CD3 T-cell engager used for the the treatment of adult patients with relapsed or refractory lymphoma after two or more lines of systemic therapy.

Lunsumio works by helping your immune system slow or stop the spread of cancer cells.

Lunsumio is injected into a vein. It is given by your care team in a hospital or clinic setting.

Lunsumio is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Lunsumio:

• Back pain
• Cough
• Fatigue
• Headache
• Muscle pain

Serious side effects are rare with Lunsumio. Side effects that you should report to your care team as soon as possible:

• Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat
• Fever, chills, unusual weakness or fatigue, loss of appetite, nausea, headache, dizziness, feeling faint or lightheaded, shortness of breath, fast or irregular heartbeat, which may be signs of cytokine release syndrome
• Infection—fever, chills, cough, sore throat, wounds that don’t heal, pain or trouble when passing urine, general feeling of discomfort or being unwell
• Low red blood cell level—unusual weakness or fatigue, dizziness, headache, trouble breathing
• Pain, tingling, or numbness in the hands or feet, muscle weakness, headache, change in vision, confusion or trouble speaking, dizziness, loss of balance or coordination, trouble walking, tremors or shaking, seizures
• Swelling and pain of the tumor site or lymph nodes
• Unusual bruising or bleeding

The following medications may interact with Lunsumio:

• Monitor for toxicity or concentrations of drugs that are CYP450 substrates where minimal concentration changes may lead to serious adverse reactions. Consult the concomitant CYP450 substrate drug prescribing information for recommended dosage modification

Genentech, Inc.

Lunsumio may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Lunsumio.  Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with Lunsumio.
You should use an effective method of birth control during your treatment and for 3 months after the last dose of Lunsumio.

• Mosunetuzumab-AXGB